

References

- [1] Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa, 'Prediction of drug–target interaction networks from the integration of chemical and genomic spaces', *Bioinformatics*, vol. 24, no. 13, pp. i232–i240, July 2008, doi: 10.1093/bioinformatics/btn162.
- [2] J. A. DiMasi, H. G. Grabowski, and R. W. Hansen, 'Innovation in the pharmaceutical industry: New estimates of R&D costs', *J. Health Econ.*, vol. 47, pp. 20–33, May 2016, doi: 10.1016/j.jhealeco.2016.01.012.
- [3] S. M. Paul *et al.*, 'How to improve R&D productivity: the pharmaceutical industry's grand challenge', *Nat. Rev. Drug Discov.*, vol. 9, no. 3, pp. 203–214, Mar. 2010, doi: 10.1038/nrd3078.
- [4] Z. Nikraftar and M. R. Keyvanpour, 'A Comparative Analytical Review on Machine Learning Methods in DrugtargetInteractions Prediction', *Curr. Comput. Aided Drug Des.*, vol. 19, no. 5, pp. 325–355, Oct. 2023, doi: 10.2174/1573409919666230111164340.
- [5] A. Vefghi, Z. Rahmati, and M. Akbari, 'Drug-Target Interaction/Affinity Prediction: Deep Learning Models and Advances Review', *Comput. Biol. Med.*, vol. 196, p. 110438, Sept. 2025, doi: 10.1016/j.combiomed.2025.110438.
- [6] X. Ru, L. Xu, W. Han, and Q. Zou, 'In silico methods for drug-target interaction prediction', *Cell Rep. Methods*, vol. 5, no. 10, p. 101184, Oct. 2025, doi: 10.1016/j.crmeth.2025.101184.
- [7] A. Mayr *et al.*, 'Large-scale comparison of machine learning methods for drug target prediction on ChEMBL', *Chem. Sci.*, vol. 9, no. 24, pp. 5441–5451, 2018, doi: 10.1039/C8SC00148K.
- [8] X. Xia, 'Bioinformatics and Drug Discovery', *Curr. Top. Med. Chem.*, vol. 17, no. 15, pp. 1709–1726, Apr. 2017, doi: 10.2174/1568026617666161116143440.
- [9] G. M. Morris *et al.*, 'AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility', *J. Comput. Chem.*, vol. 30, no. 16, pp. 2785–2791, Dec. 2009, doi: 10.1002/jcc.21256.
- [10] D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, 'Docking and scoring in virtual screening for drug discovery: methods and applications', *Nat. Rev. Drug Discov.*, vol. 3, no. 11, pp. 935–949, Nov. 2004, doi: 10.1038/nrd1549.
- [11] H. Öztürk, A. Özgür, and E. Ozkirimli, 'DeepDTA: deep drug–target binding affinity prediction', *Bioinformatics*, vol. 34, no. 17, pp. i821–i829, Sept. 2018, doi: 10.1093/bioinformatics/bty593.
- [12] R. Chen, X. Liu, S. Jin, J. Lin, and J. Liu, 'Machine Learning for Drug-Target Interaction Prediction', *Molecules*, vol. 23, no. 9, p. 2208, Aug. 2018, doi: 10.3390/molecules23092208.
- [13] D. Weininger, 'SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules', *J. Chem. Inf. Comput. Sci.*, vol. 28, no. 1, pp. 31–36, Feb. 1988, doi: 10.1021/ci00057a005.
- [14] W. R. Pearson and D. J. Lipman, 'Improved tools for biological sequence comparison.', *Proc. Natl. Acad. Sci.*, vol. 85, no. 8, pp. 2444–2448, Apr. 1988, doi: 10.1073/pnas.85.8.2444.
- [15] K. Huang, C. Xiao, L. M. Glass, and J. Sun, 'MolTrans: Molecular Interaction Transformer for drug–target interaction prediction', *Bioinformatics*, vol. 37, no. 6, pp. 830–836, Mar. 2021, doi: 10.1093/bioinformatics/btaa880.
- [16] F. Wan *et al.*, 'DeepCPI: A Deep Learning-Based Framework for Large-Scale *in Silico* Drug Screening', *Genomics Proteomics Bioinformatics*, vol. 17, no. 5, pp. 478–495, Oct. 2019, doi: 10.1016/j.gpb.2019.04.003.
- [17] T. Nguyen, H. Le, T. P. Quinn, T. Nguyen, T. D. Le, and S. Venkatesh, 'GraphDTA: predicting drug–target binding affinity with graph neural networks', *Bioinformatics*, vol. 37, no. 8, pp. 1140–1147, May 2021, doi: 10.1093/bioinformatics/btaa921.
- [18] Z. Quan, Y. Guo, X. Lin, Z.-J. Wang, and X. Zeng, 'GraphCPI: Graph Neural Representation Learning for Compound-Protein Interaction', in *2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, San Diego, CA, USA: IEEE, Nov. 2019, pp. 717–722. doi: 10.1109/BIBM47256.2019.8983267.

- [19] L. Chen *et al.*, ‘TransformerCPI: improving compound–protein interaction prediction by sequence-based deep learning with self-attention mechanism and label reversal experiments’, *Bioinformatics*, vol. 36, no. 16, pp. 4406–4414, Aug. 2020, doi: 10.1093/bioinformatics/btaa524.
- [20] M. Gao *et al.*, ‘GraphormerDTI: A graph transformer-based approach for drug-target interaction prediction’, *Comput. Biol. Med.*, vol. 173, p. 108339, May 2024, doi: 10.1016/j.combiomed.2024.108339.
- [21] Y. Zhao *et al.*, ‘Evidential deep learning-based drug-target interaction prediction’, *Nat. Commun.*, vol. 16, no. 1, p. 6915, July 2025, doi: 10.1038/s41467-025-62235-6.
- [22] G. Liu *et al.*, ‘GraphDTI: A robust deep learning predictor of drug-target interactions from multiple heterogeneous data’, *J. Cheminformatics*, vol. 13, no. 1, p. 58, Aug. 2021, doi: 10.1186/s13321-021-00540-0.
- [23] Y.-L. Zhang, W.-T. Wang, J.-H. Guan, D. K. Jain, T.-Y. Wang, and S. K. Roy, ‘MocFormer: A Two-Stage Pre-training-Driven Transformer for Drug–Target Interactions Prediction’, *Int. J. Comput. Intell. Syst.*, vol. 17, no. 1, p. 165, June 2024, doi: 10.1007/s44196-024-00561-1.
- [24] L. Zhao, H. Wang, and S. Shi, ‘PocketDTA: an advanced multimodal architecture for enhanced prediction of drug–target affinity from 3D structural data of target binding pockets’, *Bioinformatics*, vol. 40, no. 10, p. btae594, Oct. 2024, doi: 10.1093/bioinformatics/btae594.
- [25] Y. Sun, Y. Y. Li, C. K. Leung, and P. Hu, ‘iNGNN-DTI: prediction of drug–target interaction with interpretable nested graph neural network and pretrained molecule models’, *Bioinformatics*, vol. 40, no. 3, p. btae135, Mar. 2024, doi: 10.1093/bioinformatics/btae135.
- [26] J. Lee, D. W. Jun, I. Song, and Y. Kim, ‘DLM-DTI: a dual language model for the prediction of drug-target interaction with hint-based learning’, *J. Cheminformatics*, vol. 16, no. 1, p. 14, Feb. 2024, doi: 10.1186/s13321-024-00808-1.
- [27] S. Chithrananda, G. Grand, and B. Ramsundar, ‘ChemBERTa: Large-Scale Self-Supervised Pretraining for Molecular Property Prediction’, 2020, *arXiv*. doi: 10.48550/ARXIV.2010.09885.
- [28] X.-C. Zhang *et al.*, ‘MG-BERT: leveraging unsupervised atomic representation learning for molecular property prediction’, *Brief. Bioinform.*, vol. 22, no. 6, p. bbab152, Nov. 2021, doi: 10.1093/bib/bbab152.
- [29] A. Elnaggar *et al.*, ‘ProtTrans: Toward Understanding the Language of Life Through Self-Supervised Learning’, *IEEE Trans. Pattern Anal. Mach. Intell.*, vol. 44, no. 10, pp. 7112–7127, Oct. 2022, doi: 10.1109/TPAMI.2021.3095381.
- [30] Z. Lin *et al.*, ‘Evolutionary-scale prediction of atomic-level protein structure with a language model’, *Science*, vol. 379, no. 6637, pp. 1123–1130, Mar. 2023, doi: 10.1126/science.ade2574.
- [31] G. Zhou *et al.*, ‘Uni-Mol: A Universal 3D Molecular Representation Learning Framework’, May 2022, doi: 10.26434/chemrxiv-2022-jjm0j.
- [32] C. Hsu *et al.*, ‘Learning inverse folding from millions of predicted structures’, Apr. 10, 2022, *Systems Biology*. doi: 10.1101/2022.04.10.487779.
- [33] J. Jumper *et al.*, ‘Highly accurate protein structure prediction with AlphaFold’, *Nature*, vol. 596, no. 7873, pp. 583–589, Aug. 2021, doi: 10.1038/s41586-021-03819-2.
- [34] P. Bai, F. Miljković, B. John, and H. Lu, ‘Interpretable bilinear attention network with domain adaptation improves drug-target prediction’, Jan. 19, 2023, *arXiv*: arXiv:2208.02194. doi: 10.48550/arXiv.2208.02194.
- [35] C.-F. Chen, Q. Fan, and R. Panda, ‘CrossViT: Cross-Attention Multi-Scale Vision Transformer for Image Classification’, Aug. 22, 2021, *arXiv*: arXiv:2103.14899. doi: 10.48550/arXiv.2103.14899.
- [36] H. Lin *et al.*, ‘CAT: Cross Attention in Vision Transformer’, June 10, 2021, *arXiv*: arXiv:2106.05786. doi: 10.48550/arXiv.2106.05786.
- [37] H. Kurata and S. Tsukiyama, ‘ICAN: Interpretable cross-attention network for identifying drug and target protein interactions’, *PLOS ONE*, vol. 17, no. 10, p. e0276609, Oct. 2022, doi: 10.1371/journal.pone.0276609.

- [38] X. Zeng, W. Chen, and B. Lei, 'CAT-DTI: cross-attention and Transformer network with domain adaptation for drug-target interaction prediction', *BMC Bioinformatics*, vol. 25, no. 1, p. 141, Apr. 2024, doi: 10.1186/s12859-024-05753-2.
- [39] K. Che, Q. Ning, R. Li, X. Wei, H. Li, and S. Guo, 'Cross Attention and Intra-layer Attention in Heterogeneous Graph Neural Networks for Drug-Target Interaction Prediction', *IEEE Trans. Comput. Biol. Bioinforma.*, pp. 1–12, 2025, doi: 10.1109/TCBBIO.2025.3578584.
- [40] J. Lu, J. Yang, D. Batra, and D. Parikh, 'Hierarchical Question-Image Co-Attention for Visual Question Answering', 2016, *arXiv*. doi: 10.48550/ARXIV.1606.00061.
- [41] D. S. Wishart *et al.*, 'DrugBank 5.0: a major update to the DrugBank database for 2018', *Nucleic Acids Res.*, vol. 46, no. D1, pp. D1074–D1082, Jan. 2018, doi: 10.1093/nar/gkx1037.
- [42] J. Tang *et al.*, 'Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis', *J. Chem. Inf. Model.*, vol. 54, no. 3, pp. 735–743, Mar. 2014, doi: 10.1021/ci400709d.
- [43] S. Serrano and N. A. Smith, 'Is Attention Interpretable?', June 09, 2019, *arXiv*. arXiv:1906.03731. doi: 10.48550/arXiv.1906.03731.
- [44] S. Jain and B. C. Wallace, 'Attention is not Explanation', 2019, *arXiv*. doi: 10.48550/ARXIV.1902.10186.
- [45] V. Petsiuk, A. Das, and K. Saenko, 'RISE: Randomized Input Sampling for Explanation of Black-box Models', Sept. 25, 2018, *arXiv*. arXiv:1806.07421. doi: 10.48550/arXiv.1806.07421.
- [46] Y. Liu, H. Li, Y. Guo, C. Kong, J. Li, and S. Wang, 'Rethinking Attention-Model Explainability through Faithfulness Violation Test', 2022, *arXiv*. doi: 10.48550/ARXIV.2201.12114.
- [47] H. M. Berman, 'The Protein Data Bank', *Nucleic Acids Res.*, vol. 28, no. 1, pp. 235–242, Jan. 2000, doi: 10.1093/nar/28.1.235.
- [48] J. Fleming *et al.*, 'AlphaFold Protein Structure Database and 3D-Beacons: New Data and Capabilities', *J. Mol. Biol.*, vol. 437, no. 15, p. 168967, Aug. 2025, doi: 10.1016/j.jmb.2025.168967.
- [49] N. Schneider, R. A. Sayle, and G. A. Landrum, 'Get Your Atoms in Order—An Open-Source Implementation of a Novel and Robust Molecular Canonicalization Algorithm', *J. Chem. Inf. Model.*, vol. 55, no. 10, pp. 2111–2120, Oct. 2015, doi: 10.1021/acs.jcim.5b00543.
- [50] T. A. Halgren, 'Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94', *J. Comput. Chem.*, vol. 17, no. 5–6, pp. 490–519, Apr. 1996, doi: 10.1002/(SICI)1096-987X(199604)17:5/6%3C490::AID-JCC1%3E3.0.CO;2-P.
- [51] M. Wen *et al.*, 'Deep-Learning-Based Drug-Target Interaction Prediction', *J. Proteome Res.*, vol. 16, no. 4, pp. 1401–1409, Apr. 2017, doi: 10.1021/acs.jproteome.6b00618.
- [52] H. A. AL-Ghulikah, S. A. El-Sebaey, A. K. A. Bass, and M. S. El-Zoghbi, 'New Pyrimidine-5-Carbonitriles as COX-2 Inhibitors: Design, Synthesis, Anticancer Screening, Molecular Docking, and In Silico ADME Profile Studies', *Molecules*, vol. 27, no. 21, p. 7485, Jan. 2022, doi: 10.3390/molecules27217485.
- [53] P. K. Deb, R. P. Mailabaram, B. Al-Jaidi, and M. J. Saadh, 'Molecular Basis of Binding Interactions of NSAIDs and Computer-Aided Drug Design Approaches in the Pursuit of the Development of Cyclooxygenase-2 (COX-2) Selective Inhibitors', in *Nonsteroidal Anti-Inflammatory Drugs*, A. G. A. Al-kaf, Ed., InTech, 2017. doi: 10.5772/intechopen.68318.
- [54] S. W. Rowlinson *et al.*, 'A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385', *J. Biol. Chem.*, vol. 278, no. 46, pp. 45763–45769, Nov. 2003, doi: 10.1074/jbc.M305481200.